Drug tariffs, tough competition, and a fresh analyst recommendation downgrade were the burdens pulling down Novo Nordisk (NYSE: NVO) stock on Monday. In some respects, then, it was surprising that the company's shares didn't do worse than the 0.2% slump they were hit with across that trading session. Meanwhile, the S&P 500 (SNPINDEX: ^GSPC) ended the day positively, rising by 0.3%.Monday's downgrading entity was white-shoe investment bank Morgan Stanley, whose analyst Thibault Boutherin felt compelled to rerate Novo Nordisk as an underweight (sell, in other words). Previously, the pundit had tagged it as equal weight (hold). Image source: Getty Images.Continue reading
Finance
September 29, 2025
Why Novo Nordisk Stock Slumped on Monday
Advertisement
Related Articles
FAIA Bans Live Animal Displays After PETA Concerns …
Attendees at the Florida Association of Insurance Agents’ June convention in Orlando may have noticed …
2 days, 10 hours ago
2
Public Adjuster, Already in Prison, Sentenced to Another …
A public adjuster who pleaded guilty in March to defrauding Brotherhood Mutual Insurance Co. and …
2 days, 10 hours ago
3
FAA Extends Significant Flight Cuts at Newark Through …
The Federal Aviation Administration said last Thursday it will extend significant flight cuts at Newark, …
2 days, 10 hours ago
2